Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2)
Study context
- Population
- Adults with overweight or obesity (chronic weight management)
- Planned comparison
- Efsubaglutide alfa dose regimens vs matched placebo
- Primary endpoint
- Percentage change in body weight
Methodological detailsseamless, adaptive phase 2b/3, multicentre, double-blind, placebo-controlled, prespecified dose-escalation, interim evaluation for regimen selection, independent data monitoring committee, Key secondary endpoints: categorical weight-loss thresholds, anthropometric and cardiometabolic changes, safety and tolerability; imaging substudy of ectopic fat in a subset
- Seamless, adaptive phase 2b/3
- Multicentre
- Double-blind
- Placebo-controlled
- Prespecified dose-escalation
- Interim evaluation for regimen selection
- Independent data monitoring committee
- Key secondary endpoints: categorical weight-loss thresholds, anthropometric and cardiometabolic changes, safety and tolerability; imaging substudy of ectopic fat in a subset
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2). Diabetes Obes Metab. Published 11 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →